vs

Side-by-side financial comparison of American Outdoor Brands, Inc. (AOUT) and ImmunityBio, Inc. (IBRX). Click either name above to swap in a different company.

American Outdoor Brands, Inc. is the larger business by last-quarter revenue ($57.2M vs $38.3M, roughly 1.5× ImmunityBio, Inc.). American Outdoor Brands, Inc. runs the higher net margin — 3.6% vs -161.8%, a 165.4% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs -5.0%). American Outdoor Brands, Inc. produced more free cash flow last quarter ($-14.1M vs $-71.3M).

Deckers Outdoor Corporation, doing business as Deckers Brands, is an American footwear designer and distributor founded in 1973 and based in Goleta, California. The company's portfolio of brands includes UGG, Teva, and Hoka. It was founded by Doug Otto and Karl F. Lopker.

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

AOUT vs IBRX — Head-to-Head

Bigger by revenue
AOUT
AOUT
1.5× larger
AOUT
$57.2M
$38.3M
IBRX
Growing faster (revenue YoY)
IBRX
IBRX
+412.0% gap
IBRX
407.0%
-5.0%
AOUT
Higher net margin
AOUT
AOUT
165.4% more per $
AOUT
3.6%
-161.8%
IBRX
More free cash flow
AOUT
AOUT
$57.2M more FCF
AOUT
$-14.1M
$-71.3M
IBRX

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
AOUT
AOUT
IBRX
IBRX
Revenue
$57.2M
$38.3M
Net Profit
$2.1M
$-61.9M
Gross Margin
45.6%
99.0%
Operating Margin
3.7%
-169.0%
Net Margin
3.6%
-161.8%
Revenue YoY
-5.0%
407.0%
Net Profit YoY
-33.3%
-4.7%
EPS (diluted)
$0.16
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AOUT
AOUT
IBRX
IBRX
Q4 25
$57.2M
$38.3M
Q3 25
$29.7M
$32.1M
Q2 25
$61.9M
$26.4M
Q1 25
$58.5M
$16.5M
Q4 24
$60.2M
$7.6M
Q3 24
$41.6M
$6.1M
Q2 24
$46.3M
Q1 24
$53.4M
Net Profit
AOUT
AOUT
IBRX
IBRX
Q4 25
$2.1M
$-61.9M
Q3 25
$-6.8M
$-67.3M
Q2 25
$-992.0K
$-92.6M
Q1 25
$169.0K
$-129.6M
Q4 24
$3.1M
$-59.2M
Q3 24
$-2.4M
$-85.7M
Q2 24
$-5.3M
Q1 24
$-2.9M
Gross Margin
AOUT
AOUT
IBRX
IBRX
Q4 25
45.6%
99.0%
Q3 25
46.7%
99.4%
Q2 25
40.9%
99.5%
Q1 25
44.7%
99.6%
Q4 24
48.0%
Q3 24
45.4%
Q2 24
41.9%
Q1 24
42.7%
Operating Margin
AOUT
AOUT
IBRX
IBRX
Q4 25
3.7%
-169.0%
Q3 25
-23.0%
-173.5%
Q2 25
-1.5%
-269.8%
Q1 25
0.5%
-390.1%
Q4 24
5.1%
-919.0%
Q3 24
-6.2%
-1314.3%
Q2 24
-11.9%
Q1 24
-5.4%
Net Margin
AOUT
AOUT
IBRX
IBRX
Q4 25
3.6%
-161.8%
Q3 25
-23.0%
-209.8%
Q2 25
-1.6%
-350.3%
Q1 25
0.3%
-784.9%
Q4 24
5.2%
-783.4%
Q3 24
-5.7%
-1404.0%
Q2 24
-11.5%
Q1 24
-5.4%
EPS (diluted)
AOUT
AOUT
IBRX
IBRX
Q4 25
$0.16
$-0.06
Q3 25
$-0.54
$-0.07
Q2 25
$-0.08
$-0.10
Q1 25
$0.01
$-0.15
Q4 24
$0.24
$-0.08
Q3 24
$-0.18
$-0.14
Q2 24
$-0.41
Q1 24
$-0.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AOUT
AOUT
IBRX
IBRX
Cash + ST InvestmentsLiquidity on hand
$3.1M
$242.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$170.4M
$-500.5M
Total Assets
$240.9M
$501.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AOUT
AOUT
IBRX
IBRX
Q4 25
$3.1M
$242.8M
Q3 25
$17.8M
$257.8M
Q2 25
$23.4M
$153.7M
Q1 25
$17.1M
$61.6M
Q4 24
$14.2M
$149.8M
Q3 24
$23.5M
$130.4M
Q2 24
$29.7M
Q1 24
$15.9M
Stockholders' Equity
AOUT
AOUT
IBRX
IBRX
Q4 25
$170.4M
$-500.5M
Q3 25
$167.8M
$-524.3M
Q2 25
$177.6M
$-570.7M
Q1 25
$178.7M
$-591.4M
Q4 24
$178.9M
$-489.1M
Q3 24
$175.7M
$-745.1M
Q2 24
$177.9M
Q1 24
$182.4M
Total Assets
AOUT
AOUT
IBRX
IBRX
Q4 25
$240.9M
$501.9M
Q3 25
$241.9M
$519.0M
Q2 25
$246.4M
$402.1M
Q1 25
$245.9M
$303.8M
Q4 24
$254.1M
$382.9M
Q3 24
$244.8M
$364.6M
Q2 24
$240.6M
Q1 24
$239.1M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AOUT
AOUT
IBRX
IBRX
Operating Cash FlowLast quarter
$-13.3M
$-70.4M
Free Cash FlowOCF − Capex
$-14.1M
$-71.3M
FCF MarginFCF / Revenue
-24.6%
-186.2%
Capex IntensityCapex / Revenue
1.3%
2.4%
Cash ConversionOCF / Net Profit
-6.41×
TTM Free Cash FlowTrailing 4 quarters
$-4.7M
$-308.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AOUT
AOUT
IBRX
IBRX
Q4 25
$-13.3M
$-70.4M
Q3 25
$-1.7M
$-68.9M
Q2 25
$7.8M
$-79.7M
Q1 25
$5.9M
$-85.9M
Q4 24
$-7.9M
$-85.1M
Q3 24
$-4.4M
$-98.8M
Q2 24
$14.7M
Q1 24
$13.0M
Free Cash Flow
AOUT
AOUT
IBRX
IBRX
Q4 25
$-14.1M
$-71.3M
Q3 25
$-2.0M
$-69.6M
Q2 25
$7.2M
$-80.8M
Q1 25
$4.2M
$-87.0M
Q4 24
$-8.0M
$-87.3M
Q3 24
$-5.2M
$-101.6M
Q2 24
$14.2M
Q1 24
$9.7M
FCF Margin
AOUT
AOUT
IBRX
IBRX
Q4 25
-24.6%
-186.2%
Q3 25
-6.7%
-217.2%
Q2 25
11.6%
-305.9%
Q1 25
7.2%
-526.9%
Q4 24
-13.3%
-1155.4%
Q3 24
-12.5%
-1663.2%
Q2 24
30.6%
Q1 24
18.2%
Capex Intensity
AOUT
AOUT
IBRX
IBRX
Q4 25
1.3%
2.4%
Q3 25
1.0%
2.3%
Q2 25
0.9%
4.1%
Q1 25
2.9%
6.8%
Q4 24
0.1%
28.0%
Q3 24
2.0%
45.7%
Q2 24
1.1%
Q1 24
6.2%
Cash Conversion
AOUT
AOUT
IBRX
IBRX
Q4 25
-6.41×
Q3 25
Q2 25
Q1 25
34.86×
Q4 24
-2.55×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AOUT
AOUT

Traditional Channels Net Sales$36.8M64%
E Commerce Channels Net Sales$20.4M36%

IBRX
IBRX

Segment breakdown not available.

Related Comparisons